Hallucinogen use, unspecified with other specified hallucinogen-induced disorder
ICD-10 F16.98 is a billable code used to indicate a diagnosis of hallucinogen use, unspecified with other specified hallucinogen-induced disorder.
F16.98 refers to a condition characterized by the use of hallucinogenic substances that lead to various psychological and physiological effects. Hallucinogens, such as LSD, psilocybin, and mescaline, can induce altered states of consciousness, perceptual distortions, and significant changes in mood and thought processes. The unspecified nature of this code indicates that the specific hallucinogen used is not documented, but the patient exhibits symptoms consistent with hallucinogen-induced disorders. These can include hallucinations, delusions, and significant impairment in social or occupational functioning. Treatment often involves supportive care, psychotherapy, and in some cases, pharmacotherapy to manage acute symptoms or withdrawal. Understanding the nuances of hallucinogen use and its impact on mental health is crucial for effective treatment and coding.
Detailed patient history, including substance use and mental health evaluations.
Patients presenting with acute psychosis or mood disturbances following hallucinogen use.
Consideration of underlying mental health disorders and the need for a comprehensive treatment plan.
Thorough assessment of substance use patterns and treatment history.
Patients in withdrawal or seeking treatment for hallucinogen use disorder.
Integration of behavioral therapies and support systems in treatment planning.
Used when assessing a patient for hallucinogen use disorder.
Comprehensive assessment notes detailing substance use history and current symptoms.
Psychiatric evaluations should include a thorough review of mental health history.
Common hallucinogens include LSD, psilocybin mushrooms, mescaline, and DMT. Each can lead to unique symptoms and treatment considerations.
